These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32195182)

  • 1. Identification of Novel Biomarkers in Pancreatic Tumor Tissue to Predict Response to Neoadjuvant Chemotherapy.
    Sahni S; Nahm C; Krisp C; Molloy MP; Mehta S; Maloney S; Itchins M; Pavlakis N; Clarke S; Chan D; Gill AJ; Howell VM; Samra J; Mittal A
    Front Oncol; 2020; 10():237. PubMed ID: 32195182
    [No Abstract]   [Full Text] [Related]  

  • 2. Data independent acquisition of plasma biomarkers of response to neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma.
    O'Rourke MB; Sahni S; Samra J; Mittal A; Molloy MP
    J Proteomics; 2021 Jan; 231():103998. PubMed ID: 33027703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive proteomic signatures for response of pancreatic cancer patients receiving chemotherapy.
    Peng H; Chen R; Brentnall TA; Eng JK; Picozzi VJ; Pan S
    Clin Proteomics; 2019; 16():31. PubMed ID: 31346328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant Chemotherapy Enhances Local Postoperative Histopathological Tumour Stage in Borderline Resectable Pancreatic Cancer - A Matched-Pair Analysis.
    Timmermann L; Rosumeck N; Klein F; Pratschke J; Pelzer U; Bahra M; Malinka T
    Anticancer Res; 2019 Oct; 39(10):5781-5787. PubMed ID: 31570482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does mesenteric venous imaging assessment accurately predict pathologic invasion in localized pancreatic ductal adenocarcinoma?
    Clanton J; Oh S; Kaplan SJ; Johnson E; Ross A; Kozarek R; Alseidi A; Biehl T; Picozzi VJ; Helton WS; Coy D; Dorer R; Rocha FG
    HPB (Oxford); 2018 Oct; 20(10):925-931. PubMed ID: 29753633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a serum-based miRNA signature for response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy.
    Niwa Y; Yamada S; Sonohara F; Kurimoto K; Hayashi M; Tashiro M; Iwata N; Kanda M; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujiwara M; Kodera Y
    J Transl Med; 2019 Jan; 17(1):1. PubMed ID: 30602370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring Serum VEGF in Neoadjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer: A New Strategy for Early Prediction of Treatment Response and Patient Survival.
    Wang RX; Chen S; Huang L; Zhou Y; Shao ZM
    Oncologist; 2019 Jun; 24(6):753-761. PubMed ID: 30126858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
    Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resectable Distal Pancreas Cancer: Time to Reconsider the Role of Upfront Surgery.
    Nelson DW; Chang SC; Grunkemeier G; Dehal AN; Lee DY; Fischer TD; DiFronzo LA; O'Connor VV
    Ann Surg Oncol; 2018 Dec; 25(13):4012-4019. PubMed ID: 30229418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomic identification of predictive tissue biomarkers of sensitive to neoadjuvant chemotherapy in squamous cervical cancer.
    Guo L; Zhang C; Zhu J; Yang Y; Lan J; Su G; Xie X
    Life Sci; 2016 Apr; 151():102-108. PubMed ID: 26947588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating Proteins Associated with Response and Resistance to Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.
    Chantada-Vázquez MDP; Conde-Amboage M; Graña-López L; Vázquez-Estévez S; Bravo SB; Núñez C
    Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.
    Dimitrakopoulos C; Vrugt B; Flury R; Schraml P; Knippschild U; Wild P; Hoerstrup S; Henne-Bruns D; Wuerl P; Graf R; Breitenstein S; Bond G; Beerenwinkel N; Grochola LF
    JAMA Surg; 2019 Jun; 154(6):e190484. PubMed ID: 30942874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
    Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
    J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
    Janssen QP; O'Reilly EM; van Eijck CHJ; Groot Koerkamp B
    Front Oncol; 2020; 10():41. PubMed ID: 32083002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protocol of the PANCALYZE trial: a multicenter, prospective study investigating the tumor biomarkers CXCR4, SMAD4, SOX9 and IFIT3 in patients with resected pancreatic adenocarcinoma to predict the pattern of recurrence of the disease.
    Popp FC; Popp MC; Zhao Y; Betzler C; Kropf S; Garlipp B; Benckert C; Kalinski T; Lippert H; Bruns CJ
    BMC Cancer; 2017 Mar; 17(1):229. PubMed ID: 28356064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Integrated Meta-Analysis of Secretome and Proteome Identify Potential Biomarkers of Pancreatic Ductal Adenocarcinoma.
    de Oliveira G; Freire PP; Cury SS; de Moraes D; Oliveira JS; Dal-Pai-Silva M; Reis PP; Carvalho RF
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32197468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy with gemcitabine-based regimens improves the prognosis of node positive resectable pancreatic head cancer.
    Tajima H; Ohta T; Okazaki M; Yamaguchi T; Ohbatake Y; Okamoto K; Nakanuma S; Kinoshita J; Makino I; Nakamura K; Miyashita T; Takamura H; Ninomiya I; Fushida S; Nakamura H
    Mol Clin Oncol; 2019 Aug; 11(2):157-166. PubMed ID: 31281650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery.
    Nagakawa Y; Sahara Y; Hosokawa Y; Murakami Y; Yamaue H; Satoi S; Unno M; Isaji S; Endo I; Sho M; Fujii T; Takishita C; Hijikata Y; Suzuki S; Kawachi S; Katsumata K; Ohta T; Nagakawa T; Tsuchida A
    Ann Surg Oncol; 2019 Jun; 26(6):1629-1636. PubMed ID: 30610555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Implications of Transcriptomic Changes After Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
    Orozco JIJ; Grumley JG; Matsuba C; Manughian-Peter AO; Chang SC; Chang G; Gago FE; Salomon MP; Marzese DM
    Ann Surg Oncol; 2019 Oct; 26(10):3185-3193. PubMed ID: 31342395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.